Trastuzumab-Based Combinations in Metastatic Breast Cancer: How to Make a Choice

This publication has 19 references indexed in Scilit:

• Trastuzumab‐associated cardiotoxicity
  Cancer, 2002
• Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer
  Journal of Clinical Oncology, 2002
• Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5?-dFUrd in human breast cancer models
  Cancer Chemotherapy and Pharmacology, 2002
• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
  Journal of Clinical Oncology, 2002
• Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer
  Annals of Oncology, 2001
• Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
  Journal of Clinical Oncology, 2001
• Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
  New England Journal of Medicine, 2001
• Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
  Journal of Clinical Oncology, 1999
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
  Oncogene, 1999
• Early and delayed clinical cardiotoxicity of doxorubicin
  Cancer, 1985